<DOC>
	<DOCNO>NCT03055936</DOCNO>
	<brief_summary>This phase I PK study healthy male .</brief_summary>
	<brief_title>Dose-finding Pharmacokinetic Study Healthy Males</brief_title>
	<detailed_description>This phase I , open , repeat dose , randomise PK study healthy male . The study consist 4 parallel group ( Groups 1-4 ) . All group crossover design 4 treatment period , last 7 day .</detailed_description>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>Written inform consent ( IC ) obtain . Good general health ascertain detailed medical history physical examination . Males 1865 year age inclusive screening . Body mass index ( BMI ) 1930 kg/m2 ( BMI = weight/height2 ) inclusive screening . Weight least 55 kg inclusive screening . Regular intestinal transit ( recent history recurrent constipation , diarrhoea , intestinal problem , history major gastrointestinal surgery ) . Subject partner childbearing potential agrees use adequate contraception first dose study treatment 90 day last dose study treatment . Adequate method contraception include : Hormonal contraceptive , barrier method ( condom , diaphragm , cervical cap , etc . ) combination spermicide , intrauterine device sexual abstinence . Subject agree donate sperm first dose study treatment 90 day last dose study treatment . Evidence clinically significant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolic , endocrine , neurological psychiatric disease cancer ( except local nonmelanoma skin cancer ) within previous 2 year . Any condition require regular concomitant treatment ( include vitamin herbal product ) likely need concomitant treatment study . As exception , paracetamol occasional pain allow . Any clinically significant abnormal laboratory value ECG ( prolonged QTcF &gt; 450 m QRS &gt; 120 m ) opinion investigator could interfere interpretation study result cause health risk subject take part study . Known hypersensitivity active substance excipients drug . History vasovagal collapse vagal reaction unexplained reason within previous 2 year tendency vasovagal reaction blood sampling . HR &lt; 50 bpm &gt; 90 bpm supine position 5 min rest screen visit . At screen visit : systolic BP &lt; 100 mmHg &gt; 140 mmHg supine position 5 min rest diastolic BP &lt; 50 mmHg &gt; 90 mmHg supine position 5 min rest . Creatinine &gt; 1.5 x upper limit normal ( ULN ) alanine aminotransferase aspartate aminotransferase &gt; 1.25 x ULN screen . History anaphylactic/anaphylactoid reaction . Strong tendency motion sickness . Recent current ( suspect ) drug abuse . Recent current alcohol abuse ; regular drinking 21 unit per week ( 1 unit = 4 cl spirit equivalent ) . Current use nicotinecontaining product 5 cigarette ( equivalent ) /day and/or inability refrain use nicotinecontaining product 48 h first dose period collection 24 h PK sample morning day 8 . Use caffeinecontaining beverage 600 mg caffeine/day and/or inability refrain use caffeinecontaining beverage 24 h first levodopa administration PK day ( day 7 ) collection 24 h PK sample morning day 8 . Blood donation loss significant amount blood ( &gt; 500 ml ) within 90 day first study treatment administration . Participation another investigational drug study administration another investigational drug within 60 day first study treatment administration . Veins unsuitable repeated venipuncture cannulation . Predictable poor compliance inability communicate well study centre personnel . Inability participate treatment period .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>